𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Systemic inhibition of sclerostin for treatment of osteoporosis and bone healing

✍ Scribed by W. Scott Simonet

Book ID
116323668
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
108 KB
Volume
47
Category
Article
ISSN
8756-3282

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Sclerostin antibody treatment enhances m
Sclerostin antibody treatment enhances metaphyseal bone healing in rats
✍ Fredrik Agholme; Xiaodong Li; Hanna Isaksson; Hua Zhu Ke; Per Aspenberg πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 284 KB

## Abstract Sclerostin is the product of the __SOST__ gene. Loss‐of‐function mutations in the __SOST__ gene result in a high‐bone‐mass phenotype, demonstrating that sclerostin is a negative regulator of bone mass. Primarily expressed by osteocytes in bone, sclerostin is reported to bind the LRP5/6

Inhibition of sclerostin by monoclonal a
Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones
✍ Michael S Ominsky; Chaoyang Li; Xiaodong Li; Hong L Tan; Edward Lee; Mauricio Ba πŸ“‚ Article πŸ“… 2011 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 727 KB

## Abstract Therapeutic enhancement of fracture healing would help to prevent the occurrence of orthopedic complications such as nonunion and revision surgery. Sclerostin is a negative regulator of bone formation, and treatment with a sclerostin monoclonal antibody (Scl‐Ab) results in increased bon

Bone targeting for the treatment of oste
Bone targeting for the treatment of osteoporosis
✍ Tessa Luhmann; Oliver Germershaus; JΓΌrgen Groll; Lorenz Meinel πŸ“‚ Article πŸ“… 2012 πŸ› Elsevier Science 🌐 English βš– 409 KB